CJC-1295 (without DAC)

Overview

CJC-1295 (without DAC) is a synthetic 30-amino-acid analogue of Growth Hormone-Releasing Hormone (GHRH 1–29). This modified peptide features specific amino acid substitutions designed to enhance receptor affinity and provide greater resistance to enzymatic degradation compared to native GHRH.

In research settings, the “No DAC” version is specifically utilized for its short-acting profile (half-life of approximately 30 minutes). This allows for the precise study of pulsatile growth hormone release and controlled endocrine signaling. It is a primary tool for investigating the elevation of IGF-1 levels and the downstream effects on metabolic function, muscle preservation, and cellular recovery.

Key Research Applications

CJC-1295 (No DAC) is widely used in laboratory protocols to observe the Growth Hormone axis without the long-term systemic binding associated with DAC variants:

• Pulsatile GH Secretion: Modeling the natural physiological spikes of growth hormone release from the pituitary gland.
• Synergistic Protocols: Frequently studied in combination with GH secretagogues (such as Ipamorelin or GHRP-6) to investigate amplified receptor responses.
• Metabolic & Recovery Research: Analysis of the peptide’s impact on body composition, fat loss mechanisms, and injury recovery in animal models.
• Endocrine Signaling: Investigation into GHRH receptor activation and intracellular transcriptional response analysis.

Additional Details

• Synonyms: Modified GHRH (1–29), CJC-1295 without DAC
• Content: 2mg / 5mg / 10mg per vial

Handling & Reconstitution

• Reconstitution: Use sterile water, bacteriostatic water, or a buffered aqueous solution.
• Technique: Gently swirl the vial until the solid is completely dissolved. Avoid vigorous agitation, as this can compromise the peptide’s structural integrity.
• Storage: Once reconstituted, the solution should be refrigerated and used within a specific timeframe to ensure stability. Avoid repeated freeze-thaw cycles.

Important Safety Information

For Research Use Only. This product is a synthetic GHRH analogue intended strictly for laboratory and in-vitro research. It is not for human or veterinary consumption, nor is it intended for diagnostic, therapeutic, or clinical applications. All procedures must be conducted by qualified personnel using appropriate laboratory safety measures.

References

• Teichman S.L., Neale A., Lawrence B., Gagnon C., Castaigne J.P., Frohman L.A. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006; 91(3): 799–805. PMID: 16352683. https://doi.org/10.1210/jc.2005-1536
• Frohman L.A., Downs T.R., Heimer E.P., Felix A.M. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation, 1989; 83(5): 1533–1540. PMID: 2565342. https://doi.org/10.1172/JCI114049
• Camanni F., Ghigo E., Arvat E. Growth hormone-releasing peptides and their analogs. Frontiers in Neuroendocrinology, 1998; 19(1): 47–72. PMID: 9465289. https://doi.org/10.1006/frne.1997.0158